Jawad Ishtiaq

Safety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis

Background Bruton’s tyrosine kinase (BTK) inhibitors are emerging as a potential therapy for multiple sclerosis (MS) by targeting both peripheral and central nervous system–compartmentalized inflammation. Evobrutinib is the first BTK inhibitor evaluated in randomized controlled t...